Arrowhead Pharmaceuticals (NASDAQ: ARWR), a provider of RNAi-based therapeutics, announced on Monday that it presented promising results from its pivotal Phase 3 PALISADE study at the European Society of Cardiology (ESC) Congress 2024.
The study evaluated plozasiran, an investigational RNA interference therapeutic, in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disorder characterized by extremely high triglyceride levels and an increased risk of acute pancreatitis.
Key findings included: Triglyceride Reduction: Plozasiran achieved an 80% reduction in triglyceride levels from baseline, significantly outperforming the placebo group; Acute Pancreatitis Risk: The treatment reduced the risk of developing acute pancreatitis by 83%; and Consistent Efficacy: The drug was effective in both genetically confirmed and clinically diagnosed FCS patients.
These robust results pave the way for Arrowhead to file a New Drug Application (NDA) with the FDA by the end of 2024.
Results from the study were also simultaneously published in The New England Journal of Medicine.
GenScript Biotech Corporation names new board members
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Agios receives orphan drug designation for tebapivat in MDS
TFF Pharmaceuticals partners on dry powder inhaled mRNA treatment